Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Nanologica

0.40 SEK

+0.50 %

Less than 1K followers

NICA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+0.50 %
-36.71 %
-48.72 %
-61.35 %
-73.33 %
-78.61 %
-95.72 %
-97.65 %
-97.79 %

Nanologica is a life science tools company that develops, manufactures and sells advanced input products to pharmaceutical companies. Nanologica's silica-based products are specifically designed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Nanologica operates in a global niche market for drugs for the treatment of diabetes and obesity. Nanologica was founded in 2004 and is headquartered in Södertälje.

Read more
Market cap
35.35M SEK
Turnover
19.19K SEK
Revenue
14.54M
EBIT %
-407.57 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/2
2026

Annual report '25

4/3
2026

Extraordinary general meeting '26

28/5
2026

Interim report Q1'26

All
Press releases
3rd party
ShowingAll content types
Press release2/10/2026, 8:52 AM

Jeremie Trochu föreslås som ny styrelseledamot i Nanologica AB (publ)

Nanologica
Press release2/10/2026, 8:52 AM

Jeremie Trochu Proposed as New Board Member of Nanologica AB (publ)

Nanologica
Regulatory press release1/30/2026, 7:22 AM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I NANOLOGICA AB (PUBL)

Nanologica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release1/30/2026, 7:22 AM

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NANOLOGICA AB (PUBL)

Nanologica
Regulatory press release1/30/2026, 7:16 AM

NANOLOGICA GENOMFÖR RIKTADE EMISSIONER OM TOTALT CIRKA 13,7 MSEK SAMT EN FULLT SÄKERSTÄLLD FÖRETRÄDESEMISSION OM CIRKA 82,5 MSEK

Nanologica
Regulatory press release1/30/2026, 7:16 AM

NANOLOGICA CARRIES OUT DIRECTED SHARE ISSUES OF APPROX. SEK 13.7 MILLION IN TOTAL, AND A FULLY SECURED RIGHTS ISSUE OF APPROX. SEK 82.5 MILLION

Nanologica
Regulatory press release1/29/2026, 5:07 PM

Nanologica AB (publ) förvärvar Ardena Södertälje AB

Nanologica
Regulatory press release1/29/2026, 5:07 PM

Nanologica AB (publ) Acquires Ardena Södertälje AB

Nanologica
Regulatory press release11/28/2025, 9:21 AM

Nanologica AB (publ) tar order om ca 1,5 MSEK på ny produkt

Nanologica
Regulatory press release11/28/2025, 9:21 AM

Nanologica AB (publ) Receives Order of SEK 1.5 Million on a New Product

Nanologica
Press release10/24/2025, 7:13 AM

Redeye: Nanologica (Q3 update) - Production check, now positioned for ramp up

Nanologica
Regulatory press release10/23/2025, 6:10 AM

Delårsrapport Q3 2025 Nanologica AB (publ)

Nanologica
Regulatory press release10/23/2025, 6:10 AM

Interim Report Q3 2025 Nanologica AB (publ)

Nanologica
Regulatory press release10/22/2025, 7:41 AM

Nanologica AB (publ) tar order om ca 1 MSEK i Kina

Nanologica
Regulatory press release10/22/2025, 7:41 AM

Nanologica AB (publ) Receives Order of appx. SEK 1 Million In China

Nanologica
Regulatory press release10/16/2025, 2:34 PM

Nanologica AB (publ) tar kompletterande order om ca 2,7 MSEK från kund i USA

Nanologica
Regulatory press release10/16/2025, 2:34 PM

Nanologica AB (publ) Receives Additional Order of approx. SEK 2.7 Million from Customer in the US

Nanologica
Regulatory press release10/14/2025, 9:53 AM

NANOLOGICAS VALBEREDNING UTSEDD INFÖR ÅRSSTÄMMAN 2026

Nanologica
Regulatory press release10/14/2025, 9:53 AM

NANOLOGICA ANNOUNCES NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2026

Nanologica
Regulatory press release10/1/2025, 7:55 AM

Nanologica AB (publ) tar sig in på insulinmarknaden i Kina

Nanologica
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.